Enliven CSO trust sells 5,000 shares at $29.04

Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust.

Rhea-AI Filing Summary

Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust. On February 6, 2026, The Lyssikatos Revocable Trust sold 5,000 shares of Enliven common stock at a weighted average price of $29.0438 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.

After this transaction, the trust, for which Lyssikatos serves as trustee, beneficially owned 740,188 shares of Enliven Therapeutics common stock, reported as indirectly owned.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Lyssikatos Joseph P

Role CHIEF SCIENTIFIC OFFICER

Sold 5,000 shs ($145K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$29.0438	$145K

Holdings After Transaction: Common Stock — 740,188 shares (Indirect, See footnote)

Footnotes (3)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
2. F2. This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enliven Therapeutics (ELVN) disclose in this Form 4?

Enliven Therapeutics disclosed that a trust associated with chief scientific officer Joseph P. Lyssikatos sold 5,000 shares of common stock. The sale was reported as an indirect transaction and reflects ongoing activity under a pre-established trading plan.

How many Enliven Therapeutics shares were sold and at what price?

The filing reports a sale of 5,000 Enliven Therapeutics common shares. The weighted average sale price was $29.0438 per share, based on multiple trades executed between $28.925 and $29.14 during the transaction date.

Who is the reporting person in the Enliven Therapeutics (ELVN) Form 4 filing?

The reporting person is Joseph P. Lyssikatos, chief scientific officer of Enliven Therapeutics. The shares involved are held by The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee and reports indirect beneficial ownership.

Were the Enliven Therapeutics share sales under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. Such plans pre-schedule trades, helping separate personal trading decisions from day-to-day corporate developments.

How many Enliven Therapeutics (ELVN) shares remain owned after this Form 4 transaction?

After the reported sale, the filing shows 740,188 Enliven Therapeutics common shares beneficially owned. These shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, with the chief scientific officer serving as trustee for the trust.

How was the reported sale price for Enliven Therapeutics shares calculated?

The transaction occurred through multiple trades between $28.925 and $29.14 per share. The Form 4 reports a weighted average price of $29.0438. The reporting person has agreed to provide detailed trade-by-trade pricing information upon request to regulators or shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 06:12 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		S(1)		5,000	D	$29.0438(2)	740,188	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $28.925 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

	/s/ Ben Hohl, by power of attorney	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.